Literature DB >> 19886593

[Screening for distress in women with breast cancer diagnosed for the first time: employment of HADS-D and PO-Bado].

Yesim Erim1, Mingo Beckmann, Gabriele Gerlach, Sherko Kümmel, Carsten Oberhoff, Wolfgang Senf, Rainer Kimmig.   

Abstract

OBJECTIVES: In the context of an intensification of efforts to ensure sufficient psychooncological care for breast-cancer patients, the discussion concerning valid psychometric screening instruments gains a special relevance.
METHODS: The discriminant and diagnostic validity of HADS-D and PO-Bado were investigated in a sample of 123 women with breast cancer diagnosed for the first time.
RESULTS: An ROC analysis revealed a cut-off score of greater than 9 for the subscale anxiety (sensitivity: 50%; specificity: 90%) for the use of HADS-D among breast cancer patients, whereas the recommended cut-off value was greater than 7 (sensitivity: 56%; specificity: 80%) for the subscale depression. Based on the anxiety and depression scores measured by HADS-D, 74% of the clinical cases could be classified correctly. Scores for physical and mental distress measured with PO-Bado were significantly lower in the investigated sample than in the control sample.
CONCLUSIONS: HADS-D has only a moderate sensitivity for the group at hand. PO-Bado is a comprehensive basic documentation for specific psychooncological distress, though without cut-off values it is not useful as a screening instrument.

Entities:  

Mesh:

Year:  2009        PMID: 19886593     DOI: 10.13109/zptm.2009.55.3.248

Source DB:  PubMed          Journal:  Z Psychosom Med Psychother        ISSN: 1438-3608            Impact factor:   0.791


  1 in total

1.  Psychosocial impact of prognostic genetic testing in uveal melanoma patients: a controlled prospective clinical observational study.

Authors:  Marietta Lieb; Sefik Tagay; Anja Breidenstein; Tobias Hepp; Claudia H D Le Guin; Jennifer Scheel; Dietmar R Lohmann; Norbert Bornfeld; Martin Teufel; Yesim Erim
Journal:  BMC Psychol       Date:  2020-01-31
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.